| Issue | Title | |
| Vol 2006, No 67 (2006) | Is Your Company 'Corpomorphic'? | Abstract html |
| Fintan Walton | ||
| Vol 2013, No 4 (2013) | Isis Advances Antisense Drug for Huntington’s Disease in Collaboration with Roche | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 84 (2007) | ISIS Licenses Antisense Programme to BMS for Cardiovascular collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 4 (2010) | Isis Pharmaceuticals Bags USD 35 M Up Front in Deal with GSK | Abstract |
| Debbie Tranter | ||
| Vol 2012, No 12 (2012) | Isis Pharmaceuticals Ends 2012 with an Antisense Cancer Alliance with AstraZeneca | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 1 (2015) | Isis Secures Another Big Pharma Collaborator with Janssen Antisense Drug Discovery Deal | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 76 (2006) | ISS on its own Stimulates Dynavax and AstraZeneca to collaborate on Asthma | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | ISTA and Allergan in New Vitrase® Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 7 (2021) | iTeos Therapeutics signs US$2.75 B Agreement with GlaxoSmithKline | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2004, No 48 (2004) | IVAX and Recordati in Bidding War for Polish Pharma Company | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 6 (2017) | J & J Commits up to US$1 B for Protagonist’s Preclinical Crohn’s Disease Drug | Abstract pdf html |
| Natasha Piper | ||
| Vol 2006, No 74 (2006) | J&J Active on the Deal Front | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 2 (2017) | J&J Boosts Orphan Drug Portfolio with US$30 B Takeover of Actelion’s Marketed and Late-Stage Assets | Abstract pdf |
| Jasmine Kalsi, Vipul Sikka & Heather Cartwright | ||
| Vol 2009, No 6 (2009) | J&J Buys Cougar Biotech to Boost Oncology Presence | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 10 (2009) | J&J Diversifies into Vaccines | Abstract |
| Taskin Ahmed | ||
| Vol 2020, No 8 (2020) | J&J Focuses on Immunology with US$6.5 B Momenta Buyout | Abstract pdf html |
| Michelle Liu | ||
| Vol 2024, No 6 (2024) | J&J Gains Rights to Numab Therapeutics’ Atopic Dermatitis Drug for US$1.25 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 7 (2013) | J&J Gains Successor to Zytiga® with Aragon Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 7 (2009) | J&J in US$1.5 B Alzheimer’s Pact with Elan | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 7 (2010) | J&J In-Licenses Twice in Diabetes | Abstract |
| Staff Editor | ||
| Vol 2018, No 2 (2018) | J&J Locks Theravance’s Phase I Inflammatory Bowel Disease Asset for US$1 B | Abstract pdf html |
| Natasha Berry | ||
| Vol 2022, No 11 (2022) | J&J to Acquire Abiomed for US$16.6 B | Abstract html pdf |
| Ayush Saxena | ||
| Vol 2025, No 1 (2025) | J&J to Acquire Neuropsychiatry Drug Developer Intra-Cellular Therapies for US$14.6 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2003, No 33 (2003) | J&J to Acquire Scios | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 6 (2013) | J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 68 (2006) | J&J’s Takeover of Guidant Terminated | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 11 (2018) | Janssen Adds Yuhan’s Lazertinib to its Oncology Pipeline in a US$1.25 B Deal | Abstract html pdf |
| Jawala Prasad & Michelle Liu | ||
| Vol 2022, No 2 (2022) | Janssen Bets US$1.4 B on Mersana’s ADC Platform | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2016, No 5 (2016) | Janssen Biotech Adds Tesaro’s Niraparib to its Prostate Cancer Portfolio in a US$500 M Deal | Abstract html pdf |
| Natasha Berry | ||
| Vol 2021, No 10 (2021) | Janssen Biotech Bolsters Immuno-Oncology Pipeline with Xencor’s Bispecific Antibodies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 10 (2012) | Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 6 (2016) | Janssen Biotech Secures Another DART Molecule in US$740 M Deal with MacroGenics | Abstract html pdf |
| Jawala Prasad & Heather Cartwright | ||
| Vol 2018, No 5 (2018) | Janssen Biotech to Acquire Oncolytic Virus Company BeneVir for US$1.04 B | Abstract pdf html |
| Natasha Berry | ||
| Vol 2019, No 6 (2019) | Janssen Collaborates with Genmab For HexaBody-CD38 | Abstract html pdf |
| Jasmine Kalsi & Michelle Liu | ||
| Vol 2017, No 12 (2017) | Janssen Collaborates with Idorsia on Aprocitentan | Abstract pdf html |
| Natasha Piper | ||
| Vol 2017, No 10 (2017) | Janssen Ends HCV Collaboration with Achillion Amid Crowded Market | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2014, No 11 (2014) | Janssen Gives New Lease of Life to Geron by Agreeing to License its Sole Pipeline Asset | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 5 (2023) | Janssen Signs Collaboration and License Agreement with Cellular Biomedicine to Develop CAR-T Therapies | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2014, No 6 (2014) | Janssen Strengthens Prostate Cancer Pipeline with Aduro BioTech Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 10 (2018) | Janssen Strikes US$3.75 B RNAi Partnership with Arrowhead | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 2 (2019) | Janssen to Focus on Retinal Diseases with Multi-part MeiraGTx Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 4 (2021) | Janssen Ups Influenza Investment with US$780 M Bet on Cidara’s AVC Platform | Abstract pdf html |
| Michelle Liu | ||
| Vol 2009, No 5 (2009) | Japan on the Move | Abstract |
| Fintan Walton | ||
| Vol 2007, No 83 (2007) | Japanese Pharma Broadens Horizons | Abstract |
| Business Review Editor | ||
| Vol 2013, No 3 (2013) | Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem® | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 5 (2022) | Jazz Licenses Sumitomo’s Narcolepsy Drug for US$50 M Upfront | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2021, No 3 (2021) | Jazz Pharmaceuticals Bets on Cannabis-based Medicines with US$7.2 B GW Pharmaceuticals Buy | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2012, No 5 (2012) | Jazz Pharmaceuticals Diversifies into Oncology with EUSA Pharma Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 10 (2022) | Jazz Pharmaceuticals Enters into License Agreement with Zymeworks for Zanidatamab | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2019, No 12 (2019) | Jazz Pharmaceuticals Licenses PharmaMar’s Lung Cancer Drug Lurbinectedin | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 9 (2011) | Jazz Pharmaceuticals to Diversify its Portfolio with Azur Pharma Merger | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 8 (2010) | Johnson & Johnson Plans to Enter Vaccines Market via Crucell Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 6 (2010) | Johnson & Johnson Revives Interest in Respiratory Drugs Research | Abstract |
| Debbie Tranter | ||
| Vol 2008, No 102 (2008) | Johnson & Johnson Strengthens its Biosurgical Position by Acquiring Omrix | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2011, No 5 (2011) | Johnson & Johnson to Acquire Synthes for US$21.3 B in Cash and Stock | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 56 (2005) | Johnson & Johnson’s US$25.4 B Acquisition of Guidant | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 5 (2009) | Jubilant Enters into Research Collaboration with AstraZeneca | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 97 (2008) | June Gloom? | Abstract html |
| Fintan Walton | ||
| Vol 2015, No 6 (2015) | Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9 | Abstract |
| Heather Cartwright & Keshav Mahawar | ||
| Vol 2016, No 7 (2016) | Juno Turns to Immuno-Oncology Combinations with Acquisition of RedoxTherapies | Abstract pdf html |
| Dan Roberts | ||
| Vol 2007, No 80 (2007) | Junovan (mifamurtide) | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 10 (2010) | Kadmon Pharmaceuticals Signs Three Hepatitis C Deals | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 68 (2006) | KAI and Sankyo Enter Global Alliance in Cardiovascular Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | KAI Pharmaceuticals' Candidate Get Second Chance | Abstract pdf html |
| The PharmaDeals Team | ||
| Vol 2005, No 57 (2005) | Karo Bio AB | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Karo Bio and Pfizer Form Research Collaboration to Discover and Develop ROR-Gamma Modulators | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 2 (2023) | Karuna Pays US$15 M Upfront for Goldfinch Bio’s TRPC4/5 Inhibitors | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 11 (2019) | Kasei Builds US Footprint with US$1.3 B Veloxis Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 7 (2018) | Keryx And Akebia Unite to Create a Chronic Kidney Disease Specialist | Abstract pdf html |
| Subham Nandi | ||
| Vol 2012, No 4 (2012) | Key Lessons on Royalties Too Often Learned the Hard Way | Abstract |
| Nigel Borshell | ||
| Vol 2002, No 28 (2002) | Key Oncologics to Market Eligard™ in South Africa | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | King Acquires Elan’s US Primary Care Business | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | King Acquires Meridian Medical Technologies | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | King acquires Ortho-Prefest® from J&J | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 12 (2022) | Kite Enters into License Agreement with Arcellx for CART-ddBCMA in Multiple Myeloma | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2005, No 66 (2005) | Kos Pharmaceuticals Agrees to Take on Jerini's Icatibant in North America | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 72 (2006) | Kos to Market SkyePharma’s Flutiform™ | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | KS Biomedix Secures European Deal Over TransMID™-R | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | KV Acquires Rights to Menopause Transdermal Spray | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 3 (2011) | Kyowa Hakko Kirin Makes Takeover Bid for ProStrakan to Expand in Foreign Markets | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 24 (2002) | Kyowa Hakko Kogyo Co., Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 10 (2023) | Kyowa Kirin to Acquire Orchard Therapeutics for US$477.6 M | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2006, No 70 (2006) | Labelling | Details jpg |
| Business Review Editor | ||
| Vol 2003, No 41 (2003) | Laboratoires Theramex SAM | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Last Minute Shopping: A Round-up of M&A Activity in 2005 | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Latin America: A Changing Landscape | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Leo Pharma A/S | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 11 (2018) | LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm | Abstract pdf html |
| Sharath Chandra Nakka & Michelle Liu | ||
| Vol 2018, No 9 (2018) | LEO Pharma Signs US$402 M Dermatology Deal with JW Pharmaceutical | Abstract pdf html |
| Michelle Liu & Keval Haria | ||
| Vol 2009, No 10 (2009) | LEO Re-acquires Dermatology Drug Rights from Warner Chilcott | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | LEO Targets Peplin for Skin Cancer Drug | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 72 (2006) | Let Knowledge Flow | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 89 (2007) | Letairis (ambrisentan) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Lexicon Forms Development and Financing Agreement with Symphony Capital | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | LG Life Sciences to Market Thymitaq® in Republic of Korea | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Life Technologies Gets New DNA Sequencing Technology with Ion Torrent Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 11 (2009) | Ligand Acquires Metabasis in Cash and CVR Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | Ligand Acquires Neurogen and Access to Merck Partnership | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 8 (2013) | Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 43 (2004) | Lilly Acquires AME to Optimize its Pipeline Proteins | Abstract pdf |
| Business Review Editor | ||
| 1401 - 1500 of 2581 Items | << < 10 11 12 13 14 15 16 17 18 19 > >> | |